Myriad Genetics Announces New $90 Million Asset-Based Credit Facility

Posted on

SALT LAKE CITY, July 06, 2023 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it has established a new $90 million asset-based credit facility (the “ABL Facility”) with JPMorgan Chase Bank, N.A. as administrative agent and issuing bank, and the other lender parties thereto […]

Read More

Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors

Posted on

LONDON and SALT LAKE CITY, July 03, 2023 (GLOBE NEWSWIRE) — Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled prognostic blood test for individuals with Type 2 diabetes and chronic kidney disease, announces the appointment of Catherine Coste to the Company’s Board of Directors, effective June 30, 2023. […]

Read More

Merit Medical Announces Acquisition of Dialysis Catheter Portfolio and the BioSentry® Biopsy Tract Sealant System from AngioDynamics, Inc. and Acquisition of the Surfacer® Inside-Out® Access Catheter System from Bluegrass Vascular Technologies, Inc.

Posted on

Acquisitions broaden Merit’s therapeutic platform with diverse dialysis product solutions and expand its access catheter offering Acquisitions projected to add approximately $30 million of revenue, on an annualized basis, in key strategic markets that leverage existing commercial footprint Merit re-affirms full-year 2023 financial guidance on stand-alone basis and updates full-year 2023 financial guidance to include […]

Read More

KOLOSIS BIO AND MTF BIOLOGICS FORGE STRATEGIC PARTNERSHIP TO ENTER SURGICAL INCISION MARKET

Posted on

SALT LAKE CITY, Utah – May 30, 2023 (OrthoSpineNews)- Kolosis BIO (Kolosis), a leading provider of biologics solutions, and MTF Biologics, a global tissue processor and nonprofit organization, are excited to announce their partnership in the surgical incision market. This strategic collaboration represents Kolosis BIO’s expansion into a new area of healthcare, while providing MTF […]

Read More

Sera Prognostics Announces Commercial Changes and Actions to Optimize Business for Market Success Toward Accelerating Test Adoption and Revenue

Aligning Management Team given New Refined Commercial Focus on Institutions Starting with Recent Appointment of Board Member Zhenya Lindgardt as Interim President and CEO Engages Leading Strategy House to Evaluate Best Pathways Toward Targeting Enhanced Revenue Generation at Significantly Reduced Operating Costs Nadia Altomare Expected to Move from Chief Commercial Officer to Consulting Role to […]

Read More

Altitude Lab Relocates to Gateway’s BioHive Hub

Posted on

Altitude’s new facility will be housed within Recursion’s expanded headquarters and will promote increased collaboration in Downtown Salt Lake City’s rapidly growing biotech innovation ecosystem.SALT LAKE CITY, May 25, 2023 (GLOBE NEWSWIRE) — Altitude Lab announced today that its incubator program and facility will leave Research Park to grow its operation in the Gateway’s BioHive […]

Read More

Clene Awarded Grant From National Multiple Sclerosis Society to Advance Development of CNM-Au8® in Non-Active Progressive Multiple Sclerosis

Posted on

SALT LAKE CITY, May 25, 2023 (GLOBE NEWSWIRE) — Clene, Inc. (Nasdaq: CLNN), along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that Clene has received a grant from the National Multiple Sclerosis Society (NMSS) via the […]

Read More

Renalytix selects EVERSANA® to expand commercialization of KidneyIntelX for Early-Stage Kidney Disease Prognosis Detection in Patients with Type 2 Diabetes

Posted on

Model expected to accelerate deployment of KidneyIntelX across key U.S. regions with high rates of diabetic kidney disease and established insurance coverage LONDON and CHICAGO, May 25, 2023 (GLOBE NEWSWIRE) — Renalytix (NASDAQ: RNLX) (LSE: RENX), the first company to develop and commercialize an artificial intelligence (AI) powered in-vitro diagnostic for kidney disease, has selected […]

Read More

MedVenture Health Acquires Canyon Labs in Move to Bolster Services

Posted on

In a strategic move to further enhance its service offering, MedVenture Health has announced the acquisition of Canyon Labs to add regulatory and laboratory testing services to its deep portfolio. SALT LAKE CITY, UT / ACCESSWIRE / May 19, 2023 / MedVenture Health, a specialized private investment firm devoted to the advancement of medical devices, […]

Read More

Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer

Posted on

Biomarker offers another companion diagnostic option to establish eligibility for FDA-approved drug ELAHERE® SALT LAKE CITY, May 24, 2023 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the addition of Folate Receptor Alpha (FRα) to its Precise™ Oncology Solutions portfolio. The new biomarker adds another […]

Read More

Canary Speech Accelerates AI Speech Analysis Technology with Microsoft Cloud for Healthcare Integration

Posted on

Digital vocal biomarker innovator integrates clinical-grade technology providing real-time speech analysis on Microsoft Cloud for Healthcare. PROVO, Utah, May 24, 2023 /PRNewswire/ — Canary Speech, Inc. announced today that it will apply the power of artificial intelligence (AI) voice analysis technology to address a variety of mental health challenges and enable early intervention, reduce healthcare […]

Read More

Dynatronics Announces Planned Resignation of John Krier as CEO; Brian Baker Appointed President and CEO Successor after Transition

EAGAN, MN / ACCESSWIRE / May 18, 2023 / Dynatronics Corporation (NASDAQ:DYNT), a leading manufacturer of athletic training, physical therapy, and rehabilitation products, today announced that Chief Executive Officer and Director John Krier has informed the Board of his intention to resign from the company by the end of September 2023 to pursue other professional […]

Read More